We are pleased to share that the Center for Drug Evaluation of China’s NMPA has granted Breakthrough Therapy Designation to ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) for certain lung cancer patients after progression on EGFRi therapy. hutch-med.com/orpathys-tagri…

HUTCHMED will receive a US$10 million milestone payment from its partner Takeda following the national reimbursement recommendation for FRUZAQLA® (fruquintinib) in Spain in December 2024. This is the first national reimbursement recommendation in Europe. hutch-med.com/first-european…

HUTCHMED is honored with several accolades across multiple categories in the ESG Leading Enterprises 2024 campaign by Bloomberg Businessweek, including ESG Leading Enterprise, Leading Social Initiatives, and Special Category: Sustainable Supply Chain linkedin.com/feed/update/ur…

HUTCHMED announces US$608 million divestment of non-core joint venture, allowing us to further focus on our core innovative medicines business, including advancing our next-generation antibody-targeted-therapy conjugate (ATTC) programs. hutch-med.com/hutchmed-annou…

We are pleased to share that the New Drug Application for the ORPATHYS® plus TAGRISSO® in lung cancer patients with MET amplification after progression on first-line EGFR inhibitor has been accepted and granted priority review in China. hutch-med.com/orpathys-tagri…

ORPATHYS® (savolitinib) has been approved by the China NMPA for locally advanced or metastatic NSCLC with MET exon 14 skipping alteration. The new label indication will now include both treatment-naïve and previously treated patients in China. hutch-med.com/nmpa-full-appr…

We are pleased to announce that we have completed enrollment of a Phase II registration trial of fanregratinib (HMPL-453) for intrahepatic cholangiocarcinoma (IHCC) patients with FGFR2 fusion/rearrangement in China. hutch-med.com/hmpl-453-ihcc-…

We are pleased to share that the FRUSICA-2 Phase II/III clinical trial evaluating fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma in China has met its primary endpoint of PFS. hutch-med.com/frusica2-china…

We are delighted to report our 2024 Full Year Results. HUTCHMED had a highly successful year, delivering against our strategy, in the clinic and commercially with our transformational medicines.hutch-med.com/2024-full-year…

New and updated data from several studies of compounds discovered by HUTCHMED, including data from savolitinib SAVANNAH Phase II study, will be presented at the European Lung Cancer Congress (ELCC) 2025, taking place on March 26-29, 2025 in Paris, France. hutch-med.com/elcc25/

We are happy to share that TAZVERIK® (tazemetostat) has been granted conditional approval in China for the treatment of relapsed or refractory follicular lymphoma. This approval marks the first nationwide regulatory approval for TAZVERIK® in China. hutch-med.com/tazverik-nmpa-…

We are pleased to announce that we have completed enrollment of the registration phase of a Phase II trial of savolitinib in gastric cancer patients with MET amplification. hutch-med.com/hutchmed-compl…

New and updated data from savolitinib, fruquintinib and surufatinib will be presented at the upcoming American Association of Cancer Research Annual Meeting 2025 #AACR25, taking place on April 25-30, 2025 in Chicago, Illinois. hutch-med.com/aacr25/

S&P Global recently published the S&P Global Sustainability Yearbook China 2025. HUTCHMED was recognized for its outstanding performance, ranking top 10% of the 2024 Corporate Sustainability Assessment and securing its first-ever inclusion in the Yearbook. spglobal.com/esg/csa/yearbo…

New data from studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology #ASCO25 Annual Meeting taking place on May 30 – June 3 in Chicago. hutch-med.com/asco25/

We are pleased to share that the New Drug Application for the combination of fruquintinib and sintilimab for the treatment of patients with advanced renal cell carcinoma has been accepted for review by the China NMPA. hutch-med.com/china-nda-acce…

We will be announcing our 2025 interim results on Thursday, August 7, 2025. Management team of HUTCHMED will host a presentation for analysts and investors to discuss the interim financial results, followed by a Q&A session.

We are delighted to report our 2025 Half Year Results and provide updates on key clinical and commercial developments. hutch-med.com/2025-half-year…